WVP
PBYI icon

Worth Venture Partners’s Puma Biotechnology PBYI Stock Holding History

Worth Venture Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20,000
Closed -$5K – 107
2018
Q4 		$5K Buy
+20,000
New +$600K ﹤0.01% 89

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Worth Venture Partners's PBYI Position: Q4 2021 in Review

Worth Venture Partners sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 197,960 shares — an estimated $1.39M sold.

Worth Venture Partners first reported a position in PBYI in Q4 2018 and held it in 4 quarters. The position peaked at $2.4M in Q2 2021. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • Worth Venture Partners reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Worth Venture Partners sold 197,960 Puma Biotechnology shares in Q4 2021, an estimated $1.39M.
  • Worth Venture Partners first reported a position in Puma Biotechnology in Q4 2018 and held it in 4 quarters.
  • Worth Venture Partners's Puma Biotechnology position peaked at $2.4M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Worth Venture Partners's 13F filing for Q4 2021, filed 14 Feb 2022.